Trial Outcomes & Findings for Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis (NCT NCT01694485)

NCT ID: NCT01694485

Last Updated: 2019-06-27

Results Overview

Remission was defined as a total Mayo Score ≤ 2 points, with no individual subscore \> 1 point. The Mayo Score is a composite index of four items (stool frequency, rectal bleeding, rectosigmoidoscopy findings, and physician's global assessment) with each item graded semi-quantitatively on a score of 0 to 3 where 0 represents normal and higher score represents more severe disease status. The total Mayo Score is the sum of the four item scores, with a result ranging from 0 to 12 points. Higher scores represent more severe disease. The remission rate (percentage of participants with remission) was calculated based on observed data (unadjusted remission rate) and also after applying a logistic regression model including the factors of treatment group, stratification factors (prior anti-TNF use and pre- versus post-Protocol Amendment 3) and baseline total Mayo Score (adjusted remission rate).

• Recruitment status: COMPLETED
• Study phase: PHASE2
• Target enrollment: 359 participants
• Primary outcome timeframe: Week 8
• Results posted on: 2019-06-27

Participant Flow

Participants were enrolled at 92 centers located in North America, Europe, and Australia from 16 November 2012 to 11 May 2015. The study consisted of a 24-week double-blind treatment period, a 108-week open-label treatment period, and a safety follow-up period.

Participants were to be randomly assigned in a 2:1:2:2:2 ratio to 1 of 5 treatment groups. Due to a misalignment error, some participants were erroneously assigned to incorrect treatment resulting in a final randomization ratio different from that originally stipulated in the protocol.

Participant milestones

Measure	Placebo/Abrilumab 210 mg Q3M Participants randomized to receive placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24. During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks.	Abrilumab 7 mg Q4W/Abrilumab 210 mg Q3M Participants randomized to receive 7 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks (Q4W) thereafter until week 24. During the open-label period, participants received abrilumab 210 mg once every 3 months for 108 weeks.	Abrilumab 21 mg Q4W/Abrilumab 210 mg Q3M Participants randomized to receive 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24. During the open-label period, participants received abrilumab 210 mg once every 3 months for 108 weeks.	Abrilumab 70 mg Q4W/Abrilumab 210 mg Q3M Participants randomized to receive 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24. During the open-label period, participants received abrilumab 210 mg once every 3 months for 108 weeks.	Abrilumab 210 mg/Abrilumab 210 mg Q3M Participants randomized to receive a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24. During the open-label period, participants received abrilumab 210 mg once every 3 months for 108 weeks.
Overall Study STARTED	117	22	40	100	80
Overall Study Received Treatment	116	21	40	98	79
Overall Study Completed Week 8 Assessment	106	18	38	94	76
Overall Study Entered Open-label Period	100	19	36	88	68
Overall Study COMPLETED	84	15	27	62	55
Overall Study NOT COMPLETED	33	7	13	38	25

Reasons for withdrawal

Measure	Placebo/Abrilumab 210 mg Q3M Participants randomized to receive placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24. During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks.	Abrilumab 7 mg Q4W/Abrilumab 210 mg Q3M Participants randomized to receive 7 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks (Q4W) thereafter until week 24. During the open-label period, participants received abrilumab 210 mg once every 3 months for 108 weeks.	Abrilumab 21 mg Q4W/Abrilumab 210 mg Q3M Participants randomized to receive 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24. During the open-label period, participants received abrilumab 210 mg once every 3 months for 108 weeks.	Abrilumab 70 mg Q4W/Abrilumab 210 mg Q3M Participants randomized to receive 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24. During the open-label period, participants received abrilumab 210 mg once every 3 months for 108 weeks.	Abrilumab 210 mg/Abrilumab 210 mg Q3M Participants randomized to receive a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24. During the open-label period, participants received abrilumab 210 mg once every 3 months for 108 weeks.
Overall Study Withdrawal by Subject	20	6	7	25	18
Overall Study Sponsor Decision	3	0	0	2	0
Overall Study Lost to Follow-up	9	1	6	10	7
Overall Study Death	1	0	0	1	0

Baseline Characteristics

Participants with available data

Baseline characteristics by cohort

Measure	Placebo n=117 Participants Participants randomized to receive placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 7 mg Q4W n=22 Participants Participants randomized to receive 7 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 21 mg Q4W n=40 Participants Participants randomized to receive 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 70 mg Q4W n=100 Participants Participants randomized to receive 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 210 mg n=80 Participants Participants randomized to receive a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Total n=359 Participants Total of all reporting groups
Age, Continuous	41.0 years STANDARD_DEVIATION 13.3 • n=117 Participants	42.0 years STANDARD_DEVIATION 12.4 • n=22 Participants	38.3 years STANDARD_DEVIATION 11.6 • n=40 Participants	39.3 years STANDARD_DEVIATION 12.2 • n=100 Participants	39.8 years STANDARD_DEVIATION 12.0 • n=80 Participants	40.0 years STANDARD_DEVIATION 12.5 • n=359 Participants
Age, Customized 18 - 64 years	113 Participants n=117 Participants	22 Participants n=22 Participants	40 Participants n=40 Participants	99 Participants n=100 Participants	80 Participants n=80 Participants	354 Participants n=359 Participants
Age, Customized ≥ 65 years	4 Participants n=117 Participants	0 Participants n=22 Participants	0 Participants n=40 Participants	1 Participants n=100 Participants	0 Participants n=80 Participants	5 Participants n=359 Participants
Sex: Female, Male Female	36 Participants n=117 Participants	8 Participants n=22 Participants	12 Participants n=40 Participants	32 Participants n=100 Participants	32 Participants n=80 Participants	120 Participants n=359 Participants
Sex: Female, Male Male	81 Participants n=117 Participants	14 Participants n=22 Participants	28 Participants n=40 Participants	68 Participants n=100 Participants	48 Participants n=80 Participants	239 Participants n=359 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	4 Participants n=117 Participants	0 Participants n=22 Participants	2 Participants n=40 Participants	0 Participants n=100 Participants	3 Participants n=80 Participants	9 Participants n=359 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	113 Participants n=117 Participants	22 Participants n=22 Participants	38 Participants n=40 Participants	100 Participants n=100 Participants	77 Participants n=80 Participants	350 Participants n=359 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=117 Participants	0 Participants n=22 Participants	0 Participants n=40 Participants	0 Participants n=100 Participants	0 Participants n=80 Participants	0 Participants n=359 Participants
Race/Ethnicity, Customized Asian	5 Participants n=117 Participants	2 Participants n=22 Participants	1 Participants n=40 Participants	7 Participants n=100 Participants	1 Participants n=80 Participants	16 Participants n=359 Participants
Race/Ethnicity, Customized White	109 Participants n=117 Participants	20 Participants n=22 Participants	39 Participants n=40 Participants	89 Participants n=100 Participants	78 Participants n=80 Participants	335 Participants n=359 Participants
Race/Ethnicity, Customized Other	3 Participants n=117 Participants	0 Participants n=22 Participants	0 Participants n=40 Participants	4 Participants n=100 Participants	1 Participants n=80 Participants	8 Participants n=359 Participants
Any Prior Anti-Tumor Necrosis Factor (TNF) Use Yes	69 Participants n=117 Participants	6 Participants n=22 Participants	10 Participants n=40 Participants	56 Participants n=100 Participants	39 Participants n=80 Participants	180 Participants n=359 Participants
Any Prior Anti-Tumor Necrosis Factor (TNF) Use No	48 Participants n=117 Participants	16 Participants n=22 Participants	30 Participants n=40 Participants	44 Participants n=100 Participants	41 Participants n=80 Participants	179 Participants n=359 Participants
Enrollment Prior to Protocol Amendment 3 Yes	76 Participants n=117 Participants	0 Participants n=22 Participants	0 Participants n=40 Participants	58 Participants n=100 Participants	38 Participants n=80 Participants	172 Participants n=359 Participants
Enrollment Prior to Protocol Amendment 3 No	41 Participants n=117 Participants	22 Participants n=22 Participants	40 Participants n=40 Participants	42 Participants n=100 Participants	42 Participants n=80 Participants	187 Participants n=359 Participants
Duration of Ulcerative Colitis	7.83 years STANDARD_DEVIATION 5.58 • n=116 Participants • Participants with available data	9.07 years STANDARD_DEVIATION 6.57 • n=22 Participants • Participants with available data	7.05 years STANDARD_DEVIATION 5.39 • n=40 Participants • Participants with available data	9.39 years STANDARD_DEVIATION 7.25 • n=100 Participants • Participants with available data	9.44 years STANDARD_DEVIATION 7.88 • n=80 Participants • Participants with available data	8.62 years STANDARD_DEVIATION 6.70 • n=358 Participants • Participants with available data
Total Mayo Score	8.9 units on a scale STANDARD_DEVIATION 1.5 • n=117 Participants	8.1 units on a scale STANDARD_DEVIATION 1.4 • n=22 Participants	8.6 units on a scale STANDARD_DEVIATION 1.7 • n=40 Participants	9.0 units on a scale STANDARD_DEVIATION 1.5 • n=100 Participants	9.1 units on a scale STANDARD_DEVIATION 1.4 • n=80 Participants	8.9 units on a scale STANDARD_DEVIATION 1.5 • n=359 Participants

PRIMARY outcome

Timeframe: Week 8

Population: The full analysis set includes all randomized participants who received at least 1 dose of study drug. Both unadjusted and adjusted remission rates were calculated using non-responder imputation, where participants with a missing Mayo Score at week 8 were counted as non-responders.

Remission was defined as a total Mayo Score ≤ 2 points, with no individual subscore > 1 point.

The Mayo Score is a composite index of four items (stool frequency, rectal bleeding, rectosigmoidoscopy findings, and physician's global assessment) with each item graded semi-quantitatively on a score of 0 to 3 where 0 represents normal and higher score represents more severe disease status. The total Mayo Score is the sum of the four item scores, with a result ranging from 0 to 12 points. Higher scores represent more severe disease.

The remission rate (percentage of participants with remission) was calculated based on observed data (unadjusted remission rate) and also after applying a logistic regression model including the factors of treatment group, stratification factors (prior anti-TNF use and pre- versus post-Protocol Amendment 3) and baseline total Mayo Score (adjusted remission rate).

Outcome measures

Measure	Placebo n=116 Participants Participants randomized to receive placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 7 mg Q4W n=21 Participants Participants randomized to receive 7 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 21 mg Q4W n=40 Participants Participants randomized to receive 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 70 mg Q4W n=98 Participants Participants randomized to receive 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 210 mg n=79 Participants Participants randomized to receive a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.
Percentage of Participants With Remission at Week 8 Adjusted remission rate	4.4 percentage of participants	1.6 percentage of participants	2.9 percentage of participants	13.5 percentage of participants	13.4 percentage of participants
Percentage of Participants With Remission at Week 8 Unadjusted remission rate	4.3 percentage of participants	0.0 percentage of participants	2.5 percentage of participants	13.3 percentage of participants	12.7 percentage of participants

SECONDARY outcome

Timeframe: Baseline and week 8

Population: The full analysis set includes all randomized participants who received at least 1 dose of study drug. Both unadjusted and adjusted response rates were calculated using non-responder imputation, where participants with a missing Mayo Score at week 8 were counted as non-responders.

Response was defined by a decrease from baseline in the total Mayo Score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore ≥ 1 point or an absolute rectal bleeding subscore = 0 or 1.

The Mayo Score is a composite index of four items (stool frequency, rectal bleeding, rectosigmoidoscopy findings, and physician's global assessment), each graded semi-quantitatively on a scale of 0 to 3 where 0 represents normal and higher score represents more severe disease status. The total Mayo Score is the sum of the four item scores, ranging from 0 to 12 points. Higher scores represent more severe disease.

The response rate (percentage of participants with response) was calculated based on observed data (unadjusted response rate) and also after applying a logistic regression model including the factors of treatment group, stratification factors (prior anti-TNF use and pre- versus post-Protocol Amendment 3) and baseline total Mayo Score (adjusted response rate).

Outcome measures

Measure	Placebo n=116 Participants Participants randomized to receive placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 7 mg Q4W n=21 Participants Participants randomized to receive 7 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 21 mg Q4W n=40 Participants Participants randomized to receive 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 70 mg Q4W n=98 Participants Participants randomized to receive 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 210 mg n=79 Participants Participants randomized to receive a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.
Percentage of Participants With Response at Week 8 Unadjusted response rate	25.9 percentage of participants	14.3 percentage of participants	50.0 percentage of participants	49.0 percentage of participants	46.8 percentage of participants
Percentage of Participants With Response at Week 8 Adjusted response rate	26.0 percentage of participants	12.3 percentage of participants	47.2 percentage of participants	49.4 percentage of participants	47.4 percentage of participants

SECONDARY outcome

Timeframe: Week 8

Population: The full analysis set includes all randomized participants who received at least 1 dose of study drug. Both unadjusted and adjusted healing rates were calculated using non-responder imputation, where participants with missing rectosigmoidoscopy scores at week 8 were counted as non-responders.

Mucosal healing was defined using the rectosigmoidoscopy subscore of Mayo assessment as absolute subscore for rectosigmoidoscopy of 0 or 1.

Flexible rectosigmoidoscopy was performed as part of the Mayo assessment, graded semi-quantitatively on a scale of 0 to 3 where 0 represents normal and higher score represents more severe disease status.

The healing rate (percentage of participants with mucosal healing) was calculated based on observed data (unadjusted healing rate) and also after applying a logistic regression model including the factors of treatment group, stratification factors (prior anti-TNF use and pre- versus post-Protocol Amendment 3) and baseline rectosigmoidoscopy score (adjusted healing rate).

Outcome measures

Measure	Placebo n=116 Participants Participants randomized to receive placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 7 mg Q4W n=21 Participants Participants randomized to receive 7 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 21 mg Q4W n=40 Participants Participants randomized to receive 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 70 mg Q4W n=98 Participants Participants randomized to receive 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 210 mg n=79 Participants Participants randomized to receive a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.
Percentage of Participants With Mucosal Healing at Week 8 Unadjusted healing rate	21.6 percentage of participants	14.3 percentage of participants	15.0 percentage of participants	32.7 percentage of participants	29.1 percentage of participants
Percentage of Participants With Mucosal Healing at Week 8 Adjusted healing rate	16.8 percentage of participants	12.2 percentage of participants	13.9 percentage of participants	32.2 percentage of participants	29.8 percentage of participants

SECONDARY outcome

Timeframe: Week 8 and week 24

Population: The full analysis set includes all randomized participants who received at least 1 dose of study drug. Both non-adjusted and adjusted remission rates were calculated using non-responder imputation, where participants with missing Mayo Score at week 8 or week 16 were counted as non-responders.

Remission was defined as a total Mayo Score ≤ 2 points, with no individual subscore > 1 point. Sustained remission was defined as achieving the criteria for remission at both week 8 and week 24.

The Mayo Score is a composite index of four items (stool frequency, rectal bleeding, rectosigmoidoscopy findings, and physician's global assessment), each graded semi-quantitatively on a scale of 0 to 3 where 0 represents normal and higher scores represent more severe disease status. The total Mayo Score is the sum of the four item scores, with a and ranges from 0 to 12 points. Higher scores represent more severe disease.

The remission rate (percentage of participants with sustained remission) was calculated based on observed data (unadjusted remission rate) and also after applying a logistic regression model including the factors of treatment group, stratification factors (prior anti-TNF use and pre- versus post-Protocol Amendment 3) and baseline total Mayo Score (adjusted remission rate).

Outcome measures

Measure	Placebo n=116 Participants Participants randomized to receive placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 7 mg Q4W n=21 Participants Participants randomized to receive 7 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 21 mg Q4W n=40 Participants Participants randomized to receive 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 70 mg Q4W n=98 Participants Participants randomized to receive 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 210 mg n=79 Participants Participants randomized to receive a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.
Percentage of Participants With Sustained Remission at Week 8 and Week 24 Unadjusted remission rate	2.6 percentage of participants	0.0 percentage of participants	2.5 percentage of participants	8.2 percentage of participants	3.8 percentage of participants
Percentage of Participants With Sustained Remission at Week 8 and Week 24 Adjusted remission rate	3.3 percentage of participants	1.6 percentage of participants	2.8 percentage of participants	9.1 percentage of participants	4.3 percentage of participants

Adverse Events

DB Period: Placebo

Serious events: 14 serious events

Other events: 47 other events

Deaths: 0 deaths

DB Period: Abrilumab 7 mg Q4W

Serious events: 1 serious events

Other events: 9 other events

Deaths: 0 deaths

DB Period: Abrilumab 21 mg Q4W

Serious events: 3 serious events

Other events: 16 other events

Deaths: 0 deaths

DB Period: Abrilumab 70 mg Q4W

Serious events: 5 serious events

Other events: 55 other events

Deaths: 0 deaths

DB Period: Abrilumab 210 mg

Serious events: 7 serious events

Other events: 35 other events

Deaths: 0 deaths

OL Period: Placebo/Abrilumab 210 mg Q3M

Serious events: 13 serious events

Other events: 55 other events

Deaths: 0 deaths

OL Period: Abrilumab 7 mg Q4W/210 mg Q3M

Serious events: 3 serious events

Other events: 10 other events

Deaths: 0 deaths

OL Period: Abrilumab 21 mg Q4W/210 mg Q3M

Serious events: 4 serious events

Other events: 19 other events

Deaths: 0 deaths

OL Period: Abrilumab 70 mg Q4W/210 mg Q3M

Serious events: 14 serious events

Other events: 53 other events

Deaths: 0 deaths

OL Period: Abrilumab 210 mg/210 mg Q3M

Serious events: 6 serious events

Other events: 26 other events

Deaths: 0 deaths

Serious adverse events

Measure	DB Period: Placebo n=116 participants at risk Participants received placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind (DB) treatment period.	DB Period: Abrilumab 7 mg Q4W n=20 participants at risk Participants received 7 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks (Q4W) thereafter until week 24 during the double-blind treatment period.	DB Period: Abrilumab 21 mg Q4W n=40 participants at risk Participants received 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	DB Period: Abrilumab 70 mg Q4W n=99 participants at risk Participants received 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	DB Period: Abrilumab 210 mg n=79 participants at risk Participants received a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	OL Period: Placebo/Abrilumab 210 mg Q3M n=100 participants at risk Participants who received placebo during the double-blind treatment period received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks during the open-label (OL) treatment period.	OL Period: Abrilumab 7 mg Q4W/210 mg Q3M n=18 participants at risk Participants who received 7 mg abrilumab Q4W in the DB treatment period received abrilumab 210 mg once every 3 months for 108 weeks during the open-label period.	OL Period: Abrilumab 21 mg Q4W/210 mg Q3M n=36 participants at risk During the open-label period, participants who received 21 mg abrilumab Q4W during the DB treatment period received abrilumab 210 mg once every 3 months for 108 weeks.	OL Period: Abrilumab 70 mg Q4W/210 mg Q3M n=89 participants at risk Participants who received 70 mg abrilumab Q4W during the DB treatment period received abrilumab 210 mg once every 3 months for 108 weeks during the open-label period.	OL Period: Abrilumab 210 mg/210 mg Q3M n=68 participants at risk Participants who received 210 mg abrilumab during the DB treatment period received abrilumab 210 mg once every 3 months for 108 weeks during the open-label period.
Blood and lymphatic system disorders Anaemia	0.86% 1/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.5% 1/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.0% 2/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.8% 1/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.5% 1/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Blood and lymphatic system disorders Haemolytic anaemia	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.0% 1/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Blood and lymphatic system disorders Iron deficiency anaemia	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.0% 1/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Cardiac disorders Heart valve incompetence	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.1% 1/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Abdominal pain	1.7% 2/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.5% 1/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Colitis	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.0% 1/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Colitis ulcerative	4.3% 5/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.5% 1/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 4/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.5% 2/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	6.0% 6/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 2/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.5% 4/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Diarrhoea	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.1% 1/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Gastrointestinal dysplasia	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.8% 1/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Haemorrhoids	0.86% 1/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Ileus	0.86% 1/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Large intestinal obstruction	0.86% 1/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Megacolon	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.5% 1/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Proctalgia	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.1% 1/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Rectal haemorrhage	0.86% 1/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Immune system disorders Drug hypersensitivity	0.86% 1/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Immune system disorders Sarcoidosis	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.0% 1/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Abdominal abscess	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.1% 1/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Anal abscess	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Anal infection	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.1% 1/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Cytomegalovirus infection	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.5% 1/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Erysipelas	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Gastroenteritis	0.86% 1/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Gastroenteritis bacterial	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.8% 1/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Gastrointestinal infection	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.1% 1/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Perineal abscess	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Pharyngitis streptococcal	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.1% 1/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Pneumonia	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.0% 1/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.5% 1/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Pulmonary tuberculosis	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.1% 1/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Septic shock	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Skin infection	0.86% 1/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Tonsillitis	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.1% 1/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Injury, poisoning and procedural complications Post lumbar puncture syndrome	0.86% 1/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations Alanine aminotransferase increased	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations Aspartate aminotransferase increased	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations Blood alkaline phosphatase increased	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations Norovirus test positive	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Metabolism and nutrition disorders Dehydration	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Musculoskeletal and connective tissue disorders Ankylosing spondylitis	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.1% 1/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Musculoskeletal and connective tissue disorders Arthralgia	0.86% 1/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Musculoskeletal and connective tissue disorders Arthritis	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.5% 1/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Musculoskeletal and connective tissue disorders Osteoarthritis	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.0% 1/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Epstein-Barr virus associated lymphoma	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.0% 1/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Migraine	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.0% 1/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Renal and urinary disorders Nephrolithiasis	0.86% 1/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Renal and urinary disorders Renal colic	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.0% 1/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Respiratory, thoracic and mediastinal disorders Pharyngeal haemorrhage	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.1% 1/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Skin and subcutaneous tissue disorders Pemphigoid	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.5% 1/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.

Other adverse events

Measure	DB Period: Placebo n=116 participants at risk Participants received placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind (DB) treatment period.	DB Period: Abrilumab 7 mg Q4W n=20 participants at risk Participants received 7 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks (Q4W) thereafter until week 24 during the double-blind treatment period.	DB Period: Abrilumab 21 mg Q4W n=40 participants at risk Participants received 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	DB Period: Abrilumab 70 mg Q4W n=99 participants at risk Participants received 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	DB Period: Abrilumab 210 mg n=79 participants at risk Participants received a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	OL Period: Placebo/Abrilumab 210 mg Q3M n=100 participants at risk Participants who received placebo during the double-blind treatment period received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks during the open-label (OL) treatment period.	OL Period: Abrilumab 7 mg Q4W/210 mg Q3M n=18 participants at risk Participants who received 7 mg abrilumab Q4W in the DB treatment period received abrilumab 210 mg once every 3 months for 108 weeks during the open-label period.	OL Period: Abrilumab 21 mg Q4W/210 mg Q3M n=36 participants at risk During the open-label period, participants who received 21 mg abrilumab Q4W during the DB treatment period received abrilumab 210 mg once every 3 months for 108 weeks.	OL Period: Abrilumab 70 mg Q4W/210 mg Q3M n=89 participants at risk Participants who received 70 mg abrilumab Q4W during the DB treatment period received abrilumab 210 mg once every 3 months for 108 weeks during the open-label period.	OL Period: Abrilumab 210 mg/210 mg Q3M n=68 participants at risk Participants who received 210 mg abrilumab during the DB treatment period received abrilumab 210 mg once every 3 months for 108 weeks during the open-label period.
General disorders Localised oedema	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Skin and subcutaneous tissue disorders Pruritus	1.7% 2/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.0% 1/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.8% 3/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.0% 3/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.1% 1/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.9% 2/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Blood and lymphatic system disorders Anaemia	0.86% 1/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 2/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.0% 2/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.5% 2/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 4/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.3% 3/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	6.7% 6/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.9% 2/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Blood and lymphatic system disorders Lymphadenopathy	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.5% 1/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Congenital, familial and genetic disorders Phimosis	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Ear and labyrinth disorders Vertigo	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.1% 1/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Eye disorders Eye swelling	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Abdominal pain	2.6% 3/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.5% 3/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.0% 1/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 8/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.3% 3/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	6.7% 6/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Abdominal pain lower	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.0% 1/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.0% 1/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.1% 1/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Aphthous ulcer	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.1% 1/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Colitis ulcerative	3.4% 4/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 2/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 7/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.6% 6/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	17.0% 17/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	22.2% 4/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	30.6% 11/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	24.7% 22/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	11.8% 8/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Diarrhoea	0.86% 1/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.5% 3/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.0% 3/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	6.3% 5/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.0% 2/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 2/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 5/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.5% 1/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Frequent bowel movements	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.5% 1/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.8% 1/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.5% 1/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 2/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.0% 2/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.0% 2/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Haematochezia	0.86% 1/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.5% 1/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.0% 1/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.8% 1/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Nausea	3.4% 4/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 2/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 4/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	6.3% 5/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.0% 2/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.8% 1/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 5/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.5% 1/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Vomiting	0.86% 1/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.5% 1/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.0% 3/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.5% 2/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 4/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 2/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Asthenia	2.6% 3/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.5% 1/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.0% 3/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.0% 1/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.5% 4/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.5% 1/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Fatigue	2.6% 3/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.5% 1/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.1% 8/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.8% 3/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.0% 1/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.8% 1/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.1% 1/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.5% 1/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Hyperthermia	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.1% 1/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Influenza like illness	0.86% 1/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.5% 1/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.0% 2/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.0% 2/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.5% 4/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Immune system disorders Allergy to arthropod bite	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.0% 1/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Immune system disorders Food allergy	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Candida infection	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	10.0% 2/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.0% 1/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Conjunctivitis	0.86% 1/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.0% 1/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.5% 1/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Gastroenteritis	1.7% 2/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 4/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.0% 2/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.3% 3/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.4% 3/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.5% 1/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Influenza	3.4% 4/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	10.0% 2/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.0% 2/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.0% 3/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.8% 1/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.2% 2/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Nasopharyngitis	6.0% 7/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	15.0% 6/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	9.1% 9/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	10.1% 8/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	9.0% 9/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.8% 1/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 5/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.8% 6/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Upper respiratory tract infection	1.7% 2/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 4/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 5/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 2/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 5/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Urinary tract infection	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.0% 3/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.0% 1/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.1% 1/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.5% 1/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Injury, poisoning and procedural complications Limb injury	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations Blood phosphorus decreased	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.0% 1/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations Weight decreased	0.86% 1/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.4% 3/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.5% 1/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Metabolism and nutrition disorders Dehydration	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.5% 1/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Metabolism and nutrition disorders Weight gain poor	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Musculoskeletal and connective tissue disorders Arthralgia	4.3% 5/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	10.0% 4/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	11.1% 11/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.6% 6/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	11.0% 11/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	11.1% 2/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.3% 3/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	10.1% 9/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.5% 1/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Musculoskeletal and connective tissue disorders Back pain	3.4% 4/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.0% 2/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 5/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	9.0% 8/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Musculoskeletal and connective tissue disorders Joint swelling	0.86% 1/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.5% 1/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.0% 1/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.5% 1/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Musculoskeletal and connective tissue disorders Rheumatic disorder	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lipoma	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Carpal tunnel syndrome	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Headache	6.0% 7/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 2/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	11.1% 11/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	10.1% 8/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.0% 3/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	11.1% 2/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.8% 1/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 5/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.9% 4/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Pregnancy, puerperium and perinatal conditions Pregnancy	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Renal and urinary disorders Haematuria	0.86% 1/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Renal and urinary disorders Proteinuria	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Respiratory, thoracic and mediastinal disorders Cough	1.7% 2/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.1% 5/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.5% 2/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.0% 2/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.8% 1/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.5% 4/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.5% 1/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.5% 1/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.5% 2/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Skin and subcutaneous tissue disorders Acne	0.86% 1/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.0% 2/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.0% 2/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Skin and subcutaneous tissue disorders Pruritus generalised	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.1% 1/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Skin and subcutaneous tissue disorders Rash	2.6% 3/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 4/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 5/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.1% 1/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Skin and subcutaneous tissue disorders Skin ulcer	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Skin and subcutaneous tissue disorders Swelling face	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.6% 1/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Skin and subcutaneous tissue disorders Urticaria	0.00% 0/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.0% 1/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.8% 1/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.1% 1/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Vascular disorders Hypertension	0.86% 1/116 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/40 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.1% 5/99 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/79 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.0% 1/100 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/18 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/36 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/89 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.5% 1/68 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant who was randomized to the 7 mg abrilumab arm was treated with 70 mg abrilumab and is counted in the Abrilumab 70 mg group for safety assessments in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.

Additional Information

Study Director

Amgen Inc.

Phone: 866-572-6436

Email: medinfo@amgen.com

Results disclosure agreements

• Principal investigator is a sponsor employee The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.
• Publication restrictions are in place

Restriction type: OTHER